Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques

Joost H C M Kreijtz; Yasemin Suezer; Gerrie de Mutsert; J M A van den Brand; G. van Amerongen; B S Schnierle; T. Kuiken; Ron A M Fouchier; Johannes Löwer; A D M E Osterhaus; Gerd Sutter; Guus F Rimmelzwaan

doi:10.1086/595984

Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques

Joost H C M Kreijtz, Yasemin Suezer, Gerrie de Mutsert, J M A van den Brand, G. van Amerongen, B S Schnierle, T. Kuiken, Ron A M Fouchier, Johannes Löwer, A D M E Osterhaus, Gerd Sutter, Guus F Rimmelzwaan

Department of Virology, Erasmus Medical Center, Rotterdam, The Netherlands.

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

BACKGROUND: Highly pathogenic avian influenza viruses of the H5N1 subtype have been responsible for an increasing number of infections in humans since 2003. More than 60% of infected individuals die, and new infections are reported frequently. In light of the pandemic threat caused by these events, the rapid availability of safe and effective vaccines is desirable. Modified vaccinia virus Ankara (MVA) expressing the hemagglutinin (HA) gene of H5N1 viruses is a promising candidate vaccine that induced protective immunity against infection with homologous and heterologous H5N1 influenza virus in mice.

METHODS: In the present study, we evaluated a recombinant MVA vector expressing the HA gene of H5N1 influenza virus A/Vietnam/1194/04 (MVA-HA-VN/04) in nonhuman primates. Cynomolgus macaques were immunized twice and then were challenged with influenza virus A/Vietnam/1194/04 (clade 1) or A/Indonesia/5/05 (clade 2.1) to assess the level of protective immunity.

RESULTS: Immunization with MVA-HA-VN/04 induced (cross-reactive) antibodies and prevented virus replication in the upper and lower respiratory tract and the development of severe necrotizing bronchointerstitial pneumonia.

CONCLUSION: Therefore, MVA-HA-VN/04 is a promising vaccine candidate for the induction of protective immunity against highly pathogenic H5N1 avian influenza viruses in humans.

Original language	English
Pages (from-to)	405-13
Number of pages	9
Journal	Journal of Infectious Diseases
Volume	199
Issue number	3
DOIs	https://doi.org/10.1086/595984
Publication status	Published - 1 Feb 2009

Keywords

Animals
Antibodies, Viral
Brain
Hemagglutinins
Immunohistochemistry
Influenza A Virus, H5N1 Subtype
Influenza Vaccines
Lung
Macaca fascicularis
Orthomyxoviridae Infections
Recombination, Genetic
Respiratory System
Spleen
Vaccines, Synthetic
Vaccinia virus
Journal Article
Research Support, Non-U.S. Gov't

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1086/595984

Cite this

Kreijtz, J. H. C. M., Suezer, Y., de Mutsert, G., van den Brand, J. M. A., van Amerongen, G., Schnierle, B. S., Kuiken, T., Fouchier, R. A. M., Löwer, J., Osterhaus, A. D. M. E., Sutter, G., & Rimmelzwaan, G. F. (2009). Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques. Journal of Infectious Diseases, 199(3), 405-13. https://doi.org/10.1086/595984

@article{f71bb97aaf9e429f82fa931d4a8fdc3a,

title = "Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques",

abstract = "BACKGROUND: Highly pathogenic avian influenza viruses of the H5N1 subtype have been responsible for an increasing number of infections in humans since 2003. More than 60% of infected individuals die, and new infections are reported frequently. In light of the pandemic threat caused by these events, the rapid availability of safe and effective vaccines is desirable. Modified vaccinia virus Ankara (MVA) expressing the hemagglutinin (HA) gene of H5N1 viruses is a promising candidate vaccine that induced protective immunity against infection with homologous and heterologous H5N1 influenza virus in mice.METHODS: In the present study, we evaluated a recombinant MVA vector expressing the HA gene of H5N1 influenza virus A/Vietnam/1194/04 (MVA-HA-VN/04) in nonhuman primates. Cynomolgus macaques were immunized twice and then were challenged with influenza virus A/Vietnam/1194/04 (clade 1) or A/Indonesia/5/05 (clade 2.1) to assess the level of protective immunity.RESULTS: Immunization with MVA-HA-VN/04 induced (cross-reactive) antibodies and prevented virus replication in the upper and lower respiratory tract and the development of severe necrotizing bronchointerstitial pneumonia.CONCLUSION: Therefore, MVA-HA-VN/04 is a promising vaccine candidate for the induction of protective immunity against highly pathogenic H5N1 avian influenza viruses in humans.",

keywords = "Animals, Antibodies, Viral, Brain, Hemagglutinins, Immunohistochemistry, Influenza A Virus, H5N1 Subtype, Influenza Vaccines, Lung, Macaca fascicularis, Orthomyxoviridae Infections, Recombination, Genetic, Respiratory System, Spleen, Vaccines, Synthetic, Vaccinia virus, Journal Article, Research Support, Non-U.S. Gov't",

author = "Kreijtz, {Joost H C M} and Yasemin Suezer and {de Mutsert}, Gerrie and {van den Brand}, {J M A} and {van Amerongen}, G. and Schnierle, {B S} and T. Kuiken and Fouchier, {Ron A M} and Johannes L{\"o}wer and Osterhaus, {A D M E} and Gerd Sutter and Rimmelzwaan, {Guus F}",

year = "2009",

month = feb,

day = "1",

doi = "10.1086/595984",

language = "English",

volume = "199",

pages = "405--13",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "3",

}

Kreijtz, JHCM, Suezer, Y, de Mutsert, G, van den Brand, JMA, van Amerongen, G, Schnierle, BS, Kuiken, T, Fouchier, RAM, Löwer, J, Osterhaus, ADME, Sutter, G & Rimmelzwaan, GF 2009, 'Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques', Journal of Infectious Diseases, vol. 199, no. 3, pp. 405-13. https://doi.org/10.1086/595984

Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques. / Kreijtz, Joost H C M; Suezer, Yasemin; de Mutsert, Gerrie et al.
In: Journal of Infectious Diseases, Vol. 199, No. 3, 01.02.2009, p. 405-13.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques

AU - Kreijtz, Joost H C M

AU - Suezer, Yasemin

AU - de Mutsert, Gerrie

AU - van den Brand, J M A

AU - van Amerongen, G.

AU - Schnierle, B S

AU - Kuiken, T.

AU - Fouchier, Ron A M

AU - Löwer, Johannes

AU - Osterhaus, A D M E

AU - Sutter, Gerd

AU - Rimmelzwaan, Guus F

PY - 2009/2/1

Y1 - 2009/2/1

N2 - BACKGROUND: Highly pathogenic avian influenza viruses of the H5N1 subtype have been responsible for an increasing number of infections in humans since 2003. More than 60% of infected individuals die, and new infections are reported frequently. In light of the pandemic threat caused by these events, the rapid availability of safe and effective vaccines is desirable. Modified vaccinia virus Ankara (MVA) expressing the hemagglutinin (HA) gene of H5N1 viruses is a promising candidate vaccine that induced protective immunity against infection with homologous and heterologous H5N1 influenza virus in mice.METHODS: In the present study, we evaluated a recombinant MVA vector expressing the HA gene of H5N1 influenza virus A/Vietnam/1194/04 (MVA-HA-VN/04) in nonhuman primates. Cynomolgus macaques were immunized twice and then were challenged with influenza virus A/Vietnam/1194/04 (clade 1) or A/Indonesia/5/05 (clade 2.1) to assess the level of protective immunity.RESULTS: Immunization with MVA-HA-VN/04 induced (cross-reactive) antibodies and prevented virus replication in the upper and lower respiratory tract and the development of severe necrotizing bronchointerstitial pneumonia.CONCLUSION: Therefore, MVA-HA-VN/04 is a promising vaccine candidate for the induction of protective immunity against highly pathogenic H5N1 avian influenza viruses in humans.

AB - BACKGROUND: Highly pathogenic avian influenza viruses of the H5N1 subtype have been responsible for an increasing number of infections in humans since 2003. More than 60% of infected individuals die, and new infections are reported frequently. In light of the pandemic threat caused by these events, the rapid availability of safe and effective vaccines is desirable. Modified vaccinia virus Ankara (MVA) expressing the hemagglutinin (HA) gene of H5N1 viruses is a promising candidate vaccine that induced protective immunity against infection with homologous and heterologous H5N1 influenza virus in mice.METHODS: In the present study, we evaluated a recombinant MVA vector expressing the HA gene of H5N1 influenza virus A/Vietnam/1194/04 (MVA-HA-VN/04) in nonhuman primates. Cynomolgus macaques were immunized twice and then were challenged with influenza virus A/Vietnam/1194/04 (clade 1) or A/Indonesia/5/05 (clade 2.1) to assess the level of protective immunity.RESULTS: Immunization with MVA-HA-VN/04 induced (cross-reactive) antibodies and prevented virus replication in the upper and lower respiratory tract and the development of severe necrotizing bronchointerstitial pneumonia.CONCLUSION: Therefore, MVA-HA-VN/04 is a promising vaccine candidate for the induction of protective immunity against highly pathogenic H5N1 avian influenza viruses in humans.

KW - Animals

KW - Antibodies, Viral

KW - Brain

KW - Hemagglutinins

KW - Immunohistochemistry

KW - Influenza A Virus, H5N1 Subtype

KW - Influenza Vaccines

KW - Lung

KW - Macaca fascicularis

KW - Orthomyxoviridae Infections

KW - Recombination, Genetic

KW - Respiratory System

KW - Spleen

KW - Vaccines, Synthetic

KW - Vaccinia virus

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

U2 - 10.1086/595984

DO - 10.1086/595984

M3 - Article

C2 - 19061423

SN - 0022-1899

VL - 199

SP - 405

EP - 413

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 3

ER -

Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this